Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
WO2004101805A1
Method for recombinant production of mammalian proteins and proteins obtainable by such method
AU2003294757A8
Formulations useful against hepatitis c virus infections
WO2004013633A2
Method for isolating atp binding proteins by means of immobolized protein inhibitors
AU2003249977A8
Imidazole compounds for the treatment of hepatitis c virus infections
EP1477567A1
Method for recombinant production of mammalian proteins and proteins obtainable by such method
AU2003224054A1
4,5,6,7-tretrahydrobenzo(b) thiophene derivatives and methods for medical intervention against mycrobacterial infections
DE10305138A1
Composition, useful for the prophylaxis/treatment of hepatitis C virus infection and/or associated diseases, comprises an agent e.g. selenium, all trans retinoic acid or 9-cis retinoic acid
AU2002358770A8
Human cellular enzymes as targets against hepatitis c virus infections
DE10255861A1
Preventing or treating hepatitis C virus infection comprises administering an agent that inhibits or stimulates the activity or production of human gastrointestinal glutathione peroxidase
EP1389461A1
Pyrimidones with antiviral properties
WO03006426A1
Aromatic guanylhydrazones as effective compounds against neurodiseases
AU2002312927A1
Benzo(g)quinoxaline derivatives as effective compounds against infectious diseases
EP1377833A2
Gastrointestinal glutathione peroxidase in hepatitis c virus infections
EP1402454A2
Method for generating a quantitative structure property activity relationship
AU2002249261A1
Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock
US6849409B2
Cellular kinases involved in Cytomegalovirus infection and their inhibition
EP1201765A2
Cellular kinases involved in cytomegalovirus infection and their inhibition
